Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant DDI with Esomeprazole in Healthy Adults
NCT06275841Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum observed plasma concentration of vepdegestrant alone at 168 hours, Maximum observed plasma concentration of vepdegestrant with esomeprazole at 168 hours and 2 more. Started Feb 2024; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06275841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275841.